30 closest matches · ranked by relevance
Taking Benzodiazepines for Any Reason for 3 Months · Benzodiazepine Dependence
Primary: 25% Reduction in Benzodiazepine Use — 14; 6 Participants
Adverse Effects
Primary: Completion Rate — 26 percentage of successful completers
Benzodiazepine Dependence · Opioid Dependence
Primary: Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back — 4.0; 2.3 milligrams/day
Substance Use Disorders
Primary: Participant Acceptability of the Interventions — 1; 0 Participants
Generalized Anxiety Disorder
Primary: Number of Subjects at Endpoint (Post Alprazolam Free Week 6 or Last Observation Carried Forward [LOCF] Post Alprazolam Free Week 1) Who Are Benzodiazepine Free — 20; 10…
Insomnia · Primary Insomnia · Psychophysiologic Insomnia
Primary: Sleep Latency (SL) — 1; 2; 3; 0 participants
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Benzodiazepine Dependence · Anxiety Disorders · Sleep Disturbance
Primary: Feasibility of Intervention — 67; 48 Percentage of participants
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Driving Behavior
Primary: SDLP — 35.2; 49.8; 50.0; 33.5 centimeters
Low Back Pain
Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire — 11; 11 units on a scale
Benign Prostatic Hyperplasia
Primary: Adverse Events — 431; 188; 29; 0 participants
Insomnia
Primary: Rates of Hypnotic Discontinuation — 48; 36 Participants — p=0.056
Anxiety
Primary: Change in VAS Anxiety Score Relative to Baseline After Premedication — 0.35; 0.70; 0.65; 0.25 Centimeter
Generalized Anxiety Disorder
Primary: Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 — 25.8; 24.9; 24.4; -7.7 units on a scale
Psychomotor Impairment
Primary: Standard Deviation of Lane Position (SLDP) — 40.08; 37.28; 36.06; 37.61 distance (cm)
Osteoporosis
Primary: Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs) — 231 Participants
Short-term Insomnia
Primary: Total Sleep Time — 382.9; 339.2; 256.2 minutes
Healthy
Primary: Cmax - Maximum Observed Concentration — 24.33; 23.62 ng/mL
Insomnia
Primary: Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase — 0.0; 0.0 percentage of participants
Healthy
Primary: Cmax - Maximum Observed Concentration — 28.79; 28.95 ng/mL
Healthy
Primary: Standard Deviation of Lateral Position (SDLP) — 33.2; 34.2; 35.4; 47.4 centimeter (cm) — p=<0.001
Alcoholism · Alcohol Dependence · Alcohol Drinking Related Problems
Primary: Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session — 4.11; 4.5 mini-drinks
Cannabis Use Disorder
Primary: Time to Cannabis Use Relapse — 1; 1 days
Healthy
Primary: To Determine the Impact of GABA-A Receptor Agonists (Benzodiazepines, Allopregnanolone) and Other GABA-modulating Agents (Fluoxetine) on Cortical GABA Levels by…
Alcohol Withdrawal
Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale
Generalized Anxiety Disorder
Primary: Time to Relapse in Each Treatment Condition. — 11.4; 6.3 weeks
Generalized Anxiety Disorder · Panic Disorder
Primary: Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat…
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Abuse Liability of Staccato Alprazolam
Primary: Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" — 0; 1.714; 2.143; 2.286 units on a scale